3 results for "Vasko".
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: DR Anna Koumarianou
Introduction: Rectal neuroendocrine tumors (NETs) are rarely seen, representing only 1% to 2% of all rectal tumors, and 17% gastrointestinal NETs. They are classified by site of tumor origin and by degree of differentiation.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Arzu Yaren
Keywords: rectum NEC
Introduction: The prognostic evaluation of radically removed neuroendocrine tumors (NETs) represents an important issue. The cardinal tumor features can be studied as biomarkers.
Conference: 11th Annual ENETS Conference (2014)
Presenting Author: Andrejs Vanags